NYSE American - Delayed Quote USD

AIM ImmunoTech Inc. (AIM)

0.3620 -0.0010 (-0.28%)
At close: May 31 at 4:00 PM EDT
0.3601 -0.00 (-0.52%)
Pre-Market: 8:18 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
193.0000
--
141.0000
135.0000
163.0000
140.0000
Cost of Revenue
50.0000
--
--
850.0000
806.0000
893.0000
Gross Profit
143.0000
--
141.0000
-715.0000
-643.0000
-753.0000
Operating Expense
33,498.0000
--
20,064.0000
16,344.0000
14,374.0000
11,690.0000
Operating Income
-33,355.0000
--
-19,923.0000
-17,059.0000
-15,017.0000
-12,443.0000
Net Non Operating Interest Income Expense
879.0000
--
629.0000
-67.0000
-672.0000
-338.0000
Other Income Expense
1,358.0000
--
-151.0000
-2,001.0000
1,289.0000
3,377.0000
Pretax Income
-31,118.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
-9,404.0000
Net Income Common Stockholders
-31,118.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
-9,404.0000
Diluted NI Available to Com Stockholders
-31,118.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
-9,404.0000
Basic EPS
-0.64
-0.60
-0.40
-0.40
-0.45
--
Diluted EPS
-0.64
-0.60
-0.40
-0.40
-0.45
--
Basic Average Shares
48,849.9220
48,585.4040
48,047.2880
47,339.9750
31,842.7990
--
Diluted Average Shares
48,849.9220
48,585.4040
48,047.2880
47,339.9750
31,842.7990
--
Total Operating Income as Reported
-33,355.0000
--
-19,923.0000
-18,838.0000
-15,152.0000
-12,443.0000
Total Expenses
33,548.0000
--
20,064.0000
17,194.0000
15,180.0000
12,583.0000
Net Income from Continuing & Discontinued Operation
-31,118.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
-9,404.0000
Normalized Income
-31,064.0000
--
-17,804.0000
-14,807.0000
-14,503.0000
-11,786.0000
Interest Income
951.0000
--
629.0000
--
219.0000
89.0000
Interest Expense
--
--
--
67.0000
672.0000
427.0000
Net Interest Income
879.0000
--
629.0000
-67.0000
-672.0000
-338.0000
EBIT
-34,000.0000
--
-19,923.0000
-19,060.0000
-13,728.0000
-8,977.0000
EBITDA
-33,751.0000
--
-19,667.0000
-18,285.0000
-12,995.0000
-8,185.0000
Reconciled Cost of Revenue
50.0000
--
--
850.0000
806.0000
893.0000
Reconciled Depreciation
249.0000
--
256.0000
775.0000
733.0000
792.0000
Net Income from Continuing Operation Net Minority Interest
-31,118.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
-9,404.0000
Total Unusual Items Excluding Goodwill
-54.0000
--
-1,641.0000
-4,320.0000
103.0000
2,382.0000
Total Unusual Items
-54.0000
--
-1,641.0000
-4,320.0000
103.0000
2,382.0000
Normalized EBITDA
-33,697.0000
--
-18,026.0000
-13,965.0000
-13,098.0000
-10,567.0000
12/31/2019 - 7/12/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KPRX Kiora Pharmaceuticals, Inc.
0.4930
-0.60%
 
QLGN Qualigen Therapeutics, Inc.
0.2700
-1.17%
 
PBLA Panbela Therapeutics, Inc.
0.4000
+5.24%
 
COEP Coeptis Therapeutics Holdings, Inc.
0.2704
-0.33%
 
SNGX Soligenix, Inc.
0.3150
-10.00%
 
AZTR Azitra, Inc.
0.1870
-4.10%
 
ADTX Aditxt, Inc.
1.9200
-1.54%
 
ORGS Orgenesis Inc.
0.5149
+5.95%
 
SLRX Salarius Pharmaceuticals, Inc.
0.4632
+0.37%
 
PPBT Purple Biotech Ltd
0.8075
-6.10%